Mapping the rho1 GABA(C) receptor agonist binding pocket. Constructing a complete model.
Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the mammalian brain. The GABA receptor type C (GABA(C)) is a ligand-gated ion channel with pharmacological properties distinct from the GABA(A) receptor. To date, only three binding domains in the recombinant rho1 GABA(C) receptor have been recognized among six potential regions. In this report, using the substituted cysteine accessibility method, we scanned three potential regions previously unexplored in the rho1 GABA(C) receptor, corresponding to the binding loops A, E, and F in the structural model for ligand-gated ion channels. The cysteine accessibility scanning and agonist/antagonist protection tests have resulted in the identification of residues in loops A and E, but not F, involved in forming the GABA(C) receptor agonist binding pocket. Three of these newly identified residues are in a novel region corresponding to the extended stretch of loop E. In addition, the cysteine accessibility pattern suggests that part of loop A and part of loop E have a beta-strand structure, whereas loop F is a random coil. Finally, when all of the identified ligand binding residues are mapped onto a three-dimensional homology model of the amino-terminal domain of the rho1 GABA(C) receptor, they are facing toward the putative binding pocket. Combined with previous findings, a complete model of the GABA(C) receptor binding pocket was proposed and discussed in comparison with the GABA(A) receptor binding pocket.
Sedelnikova
Anna
A
Departments of Neurobiology and Physiology and Biophysics, The Center for Biophysical Sciences and Engineering, University of Alabama at Birmingham, 35294, USA.
Smith
Craig D
CD
Zakharkin
Stanislav O
SO
Davis
Delores
D
Weiss
David S
DS
Chang
Yongchang
Y
D000595:Amino Acid Sequence; D001665:Binding Sites; D003545:Cysteine / Q000235:genetics / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D018755:GABA Agonists / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology; D018756:GABA Antagonists / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D008958:Models, Molecular; D008969:Molecular Sequence Data; D009154:Mutation / Q000235:genetics; D011437:Propylamines / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D021122:Protein Subunits / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism*; D018079:Receptors, GABA / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism*; D011963:Receptors, GABA-A / Q000737:chemistry / Q000378:metabolism; D005680:gamma-Aminobutyric Acid / Q000494:pharmacology
D018755:GABA Agonists; D018756:GABA Antagonists; C087200:GABA-C receptor; D011437:Propylamines; D021122:Protein Subunits; D018079:Receptors, GABA; D011963:Receptors, GABA-A; D005680:gamma-Aminobutyric Acid; D003545:Cysteine; C011649:3-aminopropylphosphonic acid